

1 **Increased plasma heparanase activity in COVID-19 patients**

2

3 Baranca Buijsers^{1*}, Cansu Yanginlar^{1*}, Aline de Nooijer^{2†}, Inge Grondman^{2†}, Marissa L.

4 Maciej-Hulme¹, Inge Jonkman¹, Nico A.F. Janssen², Nils Rother¹, Mark de Graaf¹, Peter

5 Pickkers^{2,3}, Matthijs Kox^{2,3}, Leo A.B. Joosten², Tom Nijenhuis¹, Mihai G. Netea^{2,4}, Luuk

6 Hilbrands¹, Frank L. van de Veerdonk², Raphaël Duivenvoorden^{1,5}, Quirijn de Mast², Johan

7 van der Vlag^{1#}

8

9 ¹Department of Nephrology, Radboud Institute for Molecular Life Sciences, Radboud
10 university medical center, Nijmegen, The Netherlands.

11 ²Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud
12 University Medical Center, Nijmegen, The Netherlands

13 ³Department of Intensive Care Medicine, Radboud University Medical Center, Nijmegen, The
14 Netherlands

15 ⁴Department of Immunology and Metabolism, Life & Medical Sciences Institute, University of
16 Bonn, Bonn, Germany

17 ⁵Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai,
18 New York, NY, USA.

19

20 *co-first †co-second

21

22 #Corresponding author:

23 Prof. Dr. Johan van der Vlag

24 Department of Nephrology (480)

25 Radboud Institute for Molecular Life Sciences

26 Radboud university medical center

27 Geert Grooteplein 10

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

28 6525 GA Nijmegen

29 The Netherlands.

30 Email: Johan.vanderVlag@radboudumc.nl

31 ORCID: 0000-0001-7843-5918

32

33 **Article type:**

34 Research Paper

35 **Abstract**

36 **Background:** Several reports suggest endothelial dysfunction and loss of endothelial barrier
37 function in COVID-19. It is well established that the endothelial glyocalyx-degrading
38 enzyme heparanase (HPSE) contributes to vascular leakage and inflammation. Low
39 molecular weight heparins (LMWH) serve as an inhibitor of heparanase. We hypothesize
40 that heparanase contributes to the pathogenesis of COVID-19, and that HPSE may be
41 inhibited by the use of LMWH.

42 **Methods:** Heparanase activity and heparan sulfate levels were measured in plasma of
43 healthy controls (n=10) and COVID-19 patients (n=48).

44 **Findings:** Heparanase activity and heparan sulfate levels were significantly elevated in
45 plasma of COVID-19 patients. There was an association between heparanase activity and
46 disease severity including the need for intensive care and mechanical ventilation, lactate
47 dehydrogenase levels and creatinine levels. Use of prophylactic low molecular weight
48 heparin in non-ICU patients was associated with a reduced HPSE activity.

49 **Interpretation:** Prophylactic doses of low molecular weight heparin reduces heparanase
50 activity in COVID-19. In addition to HPSE inhibition, low molecular weight heparin
51 contributes to anti-coagulation and may exert anti-inflammatory effects. Since there is no
52 other clinically applied heparanase inhibitor currently available, treatment of COVID-19
53 patients with low molecular weight heparins should be explored.

54 **Funding:** This study was financially supported by the Radboudumc PhD fellow program,
55 consortium grant LSHM16058-SGF (GLYCOTREAT; a collaborative project financed by the
56 PPP allowance made available by Top Sector Life Sciences & Health to the Dutch Kidney
57 Foundation to stimulate public-private partnerships), ERC Advanced grant (#833247) and a
58 Spinoza Grant of the Netherlands Organization for Scientific Research.


59

60 **Keywords:**

61 COVID-19, Heparanase, Glyocalyx, Inflammation, Vascular leakage, Heparin

62

63 **Graphical Abstract**



64

65 **Research in context**

66 **Evidence before this study**

67 Severe forms of COVID-19 present with acute respiratory disease syndrome (ARDS) and
68 proteinuria, which are both associated with a leaky vasculature. An increased activity of the
69 endothelial glycocalyx degrading enzyme heparanase (HPSE) compromises endothelial
70 barrier function. HPSE activity-mediated loss of endothelial barrier function has been
71 established for several inflammatory disease conditions including infection/sepsis, ARDS
72 and proteinuric kidney diseases.

73 **Added value of this study**

74 This study demonstrates that HPSE activity is increased in COVID-19 patients, especially in
75 those with severe disease like ICU patients. Additionally, use of prophylactic doses of low
76 molecular weight heparin (LMWH) is associated with a reduced heparanase activity in
77 COVID-19 patients.

78 **Implications of all the available evidence**

79 Increased HPSE activity in COVID-19 contributes to vascular leakage as manifested by
80 ARDS and proteinuria. LMWH inhibits HPSE activity, contributes to anti-coagulation and
81 exerts anti-inflammatory effects. Since LMWH is the only clinically approved HPSE inhibitor,
82 treatment of COVID-19 patients with therapeutic doses of LMWH should be explored.

83 Introduction

84 The coronavirus disease-2019 (COVID-19) pandemic caused by the severe acute
85 respiratory syndrome coronavirus 2 (SARS-CoV-2) has impacted widely on global health.¹
86 Severe COVID-19 usually manifests as pneumonitis or acute respiratory distress syndrome
87 (ARDS).^{2,3} Moreover, severe COVID-19 can lead to multi-organ dysfunction. Case series
88 showed that upon hospital admission 59% of COVID-19 patients had proteinuria⁴, and 22%
89 of the non-ventilated patients and 90% of the ventilated patients developed acute kidney
90 injury (AKI).⁵ Therefore, patients with more severe COVID-19 disease show a higher
91 incidence of AKI, highlighting AKI as a negative prognostic factor for the survival of COVID-
92 19 patients.^{5,6}

93 Endothelial barrier function is crucial in the regulation of fluid and protein extravasation,
94 particularly in the lungs^{7,8} and in the kidneys.^{9,10} An important role for endothelial cell
95 dysfunction in the pathogenesis of the complications of COVID-19 has been proposed by
96 several studies.^{11,12} As pulmonary edema occurs when fluid leaks into alveoli, dysfunction of
97 the endothelium is likely to contribute to pulmonary edema in COVID-19. Furthermore, it has
98 been well established that proteinuria occurs when the endothelial barrier function in the
99 glomerulus is compromised.^{9,10,13}

100 Endothelial cells are covered with a thick layer of negatively charged glycosaminoglycans
101 (GAGs), termed the glycocalyx. Heparan sulfate (HS) is the predominant sulfated GAG in
102 the glycocalyx. Due to its negative charge and sulfation pattern, HS contributes to the
103 charge-dependent barrier function and mediates the binding of chemokines and
104 selectins/integrins on leukocytes to the endothelial cell surface under inflammatory
105 conditions.¹⁴ Degradation of HS by heparanase (HPSE), the only known mammalian HS-
106 degrading enzyme, disrupts the endothelial glycocalyx. As such, shedding of the glycocalyx
107 and subsequent loss of endothelial barrier function, as observed in ARDS and proteinuric
108 kidney diseases, can be attributed to increased HPSE activity.^{7,15-17} In addition to declining
109 barrier function, HPSE generates a pro-inflammatory glycocalyx that promotes the binding of
110 chemokines, cytokines and leukocytes to the endothelial cell surface. Inhibition of HPSE

111 and/or HPSE deficiency appears to be beneficial in experimental lung and kidney
112 diseases.^{7,15-18} Notably, heparins that are currently debated to be beneficial for COVID-19
113 patients¹⁹ (*i.e.* low molecular weight heparin (LMWH)) have inhibitory effects on HPSE
114 activity.^{20,21}

115 Taken together, we hypothesize that increased HPSE activity is one of the driving forces in
116 severe COVID-19 manifestation, including ARDS and proteinuria/AKI, and that HPSE may
117 be inhibited by the use of LMWH in COVID-19.

118 **Methods**

119 **Human Samples**

120 This study was performed according to the latest version of the declaration of Helsinki and
121 guidelines for good clinical practice. The local independent ethical committee approved the
122 study protocol (CMO 2020-6344, CMO 2020-6359, CMO 2016-2923). All patients admitted
123 to the Radboud university medical center (Radboudumc) with a PCR-proven SARS-CoV-2
124 infection was asked for informed consent for participation in this study. After obtaining
125 informed consent, ethylenediaminetetraacetic acid (EDTA) blood was collected and
126 centrifuged for 10 minutes at 2954 xg at room temperature (RT), plasma was collected and
127 stored at -80 °C for later analysis. Demographic data, medical history and clinical laboratory
128 measurements were collected from the medical file and processed in encoded form in
129 electronic case report forms using Castor electronic data capture (Castor EDC, Amsterdam,
130 the Netherlands).

131

132 **HPSE activity assay**

133 The activity of HPSE in EDTA plasma was determined by an in-house developed
134 heparanase (HPSE) activity assay. Nunc maxisorp flat bottom 96 plates (Thermo scientific)
135 were coated with 10 $\mu g/ml$ HSBK (Sigma-aldrich) in optimized HS coating buffer, overnight in
136 a humidified chamber at RT. Subsequently, plates were washed with 0.05% PBS-Tween 20
137 (Sigma-Aldrich) (PBST) and blocked for minimal 2 hours with 1% bacto-gelatin (Difco
138 laboratories) in PBS at RT. Plates were washed with PBST, followed by a final washing step
139 with PBS prior to 2 hours incubation at 37°C with 4 times diluted plasma sample in HPSE
140 buffer. Samples were randomly distributed over plates. The HPSE buffer consisted of 50 mM
141 citric acid-sodium citrate (Merck) buffer supplemented with 50 mM NaCl (Merck), 1 mM
142 $CaCl_2$ (Sigma-Aldrich) and 1mM DTT (Sigma-Aldrich) at final pH 5.0. Next, plates were
143 washed with PBST and incubated with primary mouse anti-rat IgM HS antibody JM403
144 (Amsbio, cat. no. #370730-S, RRID: AB_10890960, 1 $\mu g/ml$ in PBST) for 1 hour at RT.
145 Subsequently, plates were washed with PBST and incubated with secondary goat anti-

146 mouse IgM HRP antibody (Southern Biotech, cat. no. #1020-05, RRID: AB_2794201,
147 dilution 1:10000 in PBST) for 1 hour at RT. Finally, plates were washed with PBST and
148 3,3',5,5'-tetramethylbenzidine (TMB) substrate (Invitrogen) was added and reaction was
149 stopped by addition of 2M sulfuric acid, and absorbance was measured at 450 nm. The
150 HPSE activity in plasma was related to a standard curve of recombinant human HPSE (R&D
151 systems, Cat#7570-GH-005) in healthy control EDTA plasma.

152 For the *in vitro* HPSE inhibition experiment with dalteparin (Pfizer, Fragmin 12,500 IU/0.5
153 ml), the HPSE activity was determined using the HPSE activity assay described above. For
154 inhibition 0-1 IU/ml dalteparin was used with a constant amount of 150 ng/ml recombinant
155 human HPSE (R&D systems, Cat#7570-GH-005).

156

157 **HS competition assay**

158 HS in EDTA plasma samples was quantified by an in house developed HS competition
159 assay.^{22,23} Importantly, this assay is specific to HS, therefore the measurement is not
160 affected by the presence of LMWH use. Plates were coated with HSBK and blocked with
161 bacto-gelatin as outlined for the HPSE activity assay. Uncoated plates, blocked with bacto-
162 gelatin, were washed with PBST. The plasma samples were 4 times diluted in PBST
163 containing primary mouse anti-rat IgM HS antibody JM403 (Amsbio, cat. no. #370730-S,
164 RRID: AB_10890960, 1.3 µg/ml) and incubated for 1 hour at RT. Samples were randomly
165 distributed over plates. Subsequently, the samples were transferred from the uncoated
166 plates to the HSBK-coated plates and incubated for 1 hour at RT. Plates were washed with
167 PBST and incubated with secondary goat anti-mouse IgM HRP antibody (Southern Biotech,
168 cat. no. #1020-05, RRID: AB_2794201, dilution 1:10,000) for 1 hour at RT. Plates were
169 developed and measured as outlined for the HPSE activity assay. The amount of HS
170 detected in plasma is expressed in arbitrary units since HS from bovine kidney was coated
171 and used to prepare the standard curve.

172

173 **Statistical analysis**

174 Values are expressed as mean±SEM. D'Agostino & Pearson normality test is performed to
175 test for normality of data. Significance was determined by Fisher's exact test to compare
176 categorical variable, by Student's t-test or Mann Whitney test to compare two groups and by
177 Kruskal-Wallis test followed by Dunn's test to compare more than two groups using
178 GraphPad Prism V.8.4.2 (La Jolla, USA). P values less than 0.05 were considered as
179 statistically significant.

180 **Results**

181 ***Demographics and baseline characteristics of COVID-19 patients***

182 Plasma was collected from 48 PCR-confirmed COVID-19 patients admitted to the ICU (n=
183 14) or to designated COVID-19 clinical wards (n= 34). More men than women were included
184 (Table 1). ICU patients had a significantly higher C-reactive protein concentration than non-
185 ICU patients. The non-ICU patients were further aggregated in those receiving prophylactic
186 LMWH (LMWH+) (in general dalteparin 5000 IU subcutaneously once daily) (n=17) and
187 those receiving either alternative anticoagulation (n=8; vitamin K antagonist n=6, direct oral
188 anticoagulant n=2) or patients for whom the sample collection was performed before
189 initiation of any standard medical intervention (LMWH-) (n=9). Day of sampling was
190 significantly different between ICU and non-ICU groups as well as between LMWH- and
191 LMWH+ groups. The LMWH group had significantly higher median platelet count and D-
192 dimer concentrations compared to LMWH- group, whereas the concentrations of the
193 inflammatory markers CRP and serum ferritin were similar between LMWH+ and LMWH-.

194

195 ***Plasma HPSE activity is elevated in COVID-19 patients***

196 Several (experimental) disease models have shown that increased HPSE activity can lead to
197 endothelial barrier dysfunction, which may be involved in the development of ARDS and
198 proteinuria/AKI.^{7,24,25} Measurement of plasma HPSE activity levels in COVID-19 patients and
199 healthy controls revealed that HPSE activity was significantly elevated in COVID-19 patients
200 in comparison to healthy controls (Figure 1A). In line with the increased HPSE activity, HS
201 plasma levels were also significantly elevated in COVID-19 patients compared to healthy
202 controls (Figure 1B). Overall, these results suggest that SARS-CoV-2 infection causes an
203 increase in the activity of HPSE in plasma and an increase in circulating HS.

204

205 ***HPSE activity associates with COVID-19 disease severity***

206 Next, we investigated whether HPSE activity levels were associated with COVID-19 disease
207 severity. More specifically, potential associations were assessed between HPSE activity

208 levels and the need for intensive care or for mechanical ventilation, lactate dehydrogenase
209 (LDH) values as a measure of tissue damage and creatinine values as a measure of kidney
210 function. Plasma HPSE activity was significantly higher in both non-ICU and ICU patients
211 compared to healthy controls, and HPSE levels in ICU patients were significantly higher than
212 in non-ICU patients (Figure 2A). HS levels in plasma were also significantly higher in both
213 non-ICU and ICU patients compared to healthy controls (Figure 2B). HPSE activity was also
214 significantly elevated in the plasma of patients in need of mechanical ventilation (Figure 2C).
215 Importantly, plasma HPSE activity was increased in patients with elevated LDH values (>280
216 U/l) compared to patients with LDH values within the normal range (Figure 2D). Patients with
217 elevated serum creatinine values (>110 $\mu\text{mol/l}$ for men and >90 $\mu\text{mol/l}$ for women) also
218 displayed increased plasma HPSE activity (Figure 2E). These findings reveal that patients
219 with severe COVID-19 disease, such as those admitted to the ICU department, have higher
220 plasma HPSE activity levels than patients with moderate, such as non-ICU patients, COVID-
221 19 disease.

222

223 ***Use of LMWH is associated with lower HPSE activity in plasma of COVID-19 patients***

224 Recent studies show a high rate of thromboembolic complications in patients with severe
225 COVID-19. Autopsy studies in COVID-19 patients have identified the presence of
226 coagulation in the microvasculature, which might also contribute to organ failure.^{26,27}
227 Prophylactic treatment with LMWH is therefore recommended for patients hospitalized with
228 COVID-19²⁸, whereas some experts recommend higher doses for critically ill patients. As
229 LMWH possesses HPSE inhibiting properties, the effect of prophylactic LMWH on HPSE
230 activity in plasma of COVID-19 patients was analyzed. Markedly, non-ICU patients who
231 received LMWH displayed significantly lower HPSE activity compared to non-ICU patients
232 without LMWH prophylaxis (Figure 3A). According to literature a single injection of 5000
233 units dalteparin would result in an estimated concentration of around 0.37 U/ml *in vivo*.²⁹ We
234 found a dose dependent inhibition of recombinant HPSE at concentrations between 0.0025
235 and 0.05 U/ml and full inhibition starting from 0.25 U/ml dalteparin *in vitro* (Figure 3B). These

236 data suggest that the applied prophylactic LMWH dose is already effective in inhibition of
237 HPSE activity within plasma of moderately diseased, but not severely ill, COVID-19
238 patients.

239

240 ***Treatment with chloroquine does not reduce HPSE activity in plasma of COVID-19***
241 ***patients***

242 Regarding treatments under debate for COVID-19, chloroquine (CQ) has been suggested to
243 be beneficial for the clinical outcome.^{25,30,31} Notably, it has been described that CQ can
244 prevent the cathepsin-L-mediated activation of pro-heparanase into active HPSE in the
245 lysosome.²⁰ Pro-heparanase can also be activated extracellularly as well as in the
246 lysosome³², suggesting that CQ can only partially inhibit HPSE activation. In line with this,
247 COVID-19 patients with CQ treatment did not display significantly different HPSE activity
248 levels compared to patients without CQ treatment (see S figure 1).

249 **Discussion**

250 COVID-19 appears to be a disease that leads to endothelial dysfunction and disruption of
251 the endothelial barrier, which may underly development of ARDS and proteinuria/AKI.^{11,33}

252 Here, we report increased HPSE activity and HS levels in plasma of COVID-19 patients,
253 which were also associated with severity of the disease.

254

255 Several mechanisms are currently proposed to explain pulmonary edema and ARDS in
256 COVID-19. One suggested mechanism focuses on the kallikrein/kinin system, which is
257 involved in the local inflammation and vascular leakage in the lung.^{34,35} It has been
258 suggested that over-activation of the bradykinin pathway occurs due to consumption of
259 angiotensin converting enzyme-2 (ACE2) during viral entry.³⁵ Interestingly, endothelial cell
260 surface GAGs, such as HS, regulate activation of bradykinin pathways whereas degradation
261 of HS by bacterial heparinases resumes proteolytic bradykinin generation.³⁶ These findings
262 suggest that increased HPSE activity observed in COVID-19 patients could induce activation
263 of the bradykinin pathway, thereby additionally contributing to vascular leakage and local
264 inflammation. Another possible mechanism involved in endothelial dysfunction in COVID-19
265 patients is activation of the renin-angiotensin system.³⁷ Increased angiotensin II levels have
266 been reported in COVID-19 patients.³⁸ Angiotensin II induces vasoconstriction, inflammation,
267 fibrosis and proliferation, which in turn can cause thrombosis, ARDS and AKI. Importantly,
268 we have previously shown that Angiotensin II is a potent inducer of HPSE expression.^{39,40}
269 Moreover, it is feasible that endothelin-1 (ET-1), one of the downstream mediators activated
270 by angiotensin II^{41,42} is also increased in COVID-19 and it is known that ET-1 can induce
271 HPSE expression as well.⁴³

272

273 Besides the role of HPSE in compromising the endothelial glycocalyx and in turn the
274 endothelial barrier function, HPSE and circulating HS fragments play an important role in
275 inflammation.⁴⁴ HPSE can activate macrophages inducing secretion of MCP-1, TNF- α and
276 IL-1, independent of HS-degrading activity.⁴⁵ HS fragments released by HPSE activity also

277 induce a pro-inflammatory response by binding to TLR2 and TLR4.^{45,46} Moreover, cleavage
278 of HS by HPSE releases HS bound molecules, such as chemokines and cytokines,
279 promoting inflammation.⁴⁷ Cells exposed to HPSE show an enhanced response to pro-
280 inflammatory cytokines like IFN- γ and LPS.^{17,48,49} Interestingly, cytokines such as IL-1 β , IL-6,
281 TNF- α and MCP-1 appear to be elevated in COVID-19 patients⁵⁰⁻⁵² and can induce HPSE
282 expression¹⁵, suggesting the formation of a HPSE-mediated positive feed forward loop for
283 inflammation in COVID-19. Notably, HPSE appears to have a direct effect in shaping the
284 cytokine milieu, since HPSE deficiency reduces expression of a wide range of cytokines
285 including TNF- α , IL-6, IFN- γ in experimental models.¹⁵ Therefore, inhibition of HPSE activity
286 may also partially dampen the inflammatory response observed in COVID-19 patients.

287 Heparin and LMWH are able to inhibit HPSE due to their structural similarity with HS.²¹
288 Potential beneficial effects of prophylactic as well as therapeutic doses of LMWH in COVID-
289 19 patients have been described.⁵³⁻⁵⁶ Our findings suggest that prophylactic doses of LMWH
290 were able to inhibit HPSE activity in moderately diseased, non-ICU patients, emphasizing
291 the importance of non-anticoagulant properties of LMWH against COVID-19. In ICU patients,
292 however, HPSE activity appears to remain elevated despite general use of prophylactic
293 LMWH in the ICU. Considering that HPSE activity was significantly higher in ICU patients
294 compared to non-ICU patients, therapeutic LMWH dose instead of prophylactic dose might
295 be needed to reduce HPSE activity of COVID-19 patients in the ICU. In addition to inhibition
296 of HPSE, LMWH have other non-anticoagulant functions that may be beneficial for patients
297 with COVID-19, such as neutralization of chemokines/cytokines, interference with leukocyte
298 trafficking, neutralization of extracellular cytotoxic histones, neutralization of high molecular
299 weight kinogen, and reduction of viral entry.^{36,57-59}

300 In summary, this cross-sectional study shows that HPSE activity and HS levels are
301 significantly elevated in plasma of COVID-19 patients, which is associated with the severity
302 of COVID-19. Targeting of HPSE activity could be beneficial for the clinical outcome of
303 COVID-19 patients, since it is well established that increased HPSE activity compromises

304 the endothelial glycocalyx and endothelial barrier function and contributes to the
305 establishment of a pro-inflammatory cytokine milieu. Considering the fact that no specific
306 clinically approved heparanase inhibitors are currently available, prospective studies
307 evaluating the clinical outcome of COVID-19 patients treated with therapeutic doses of
308 LMWH are urgently needed.

309 **Acknowledgements**

310 This study was financially supported by the Radboud university medical center PhD fellow
311 program and consortium grant LSHM16058-SGF (GLYCOTREAT; a collaborative project
312 financed by the PPP allowance made available by Top Sector Life Sciences & Health to the
313 Dutch Kidney Foundation to stimulate public-private partnerships) coordinated by JvdV.
314 MGN was supported by an ERC Advanced grant (#833247) and a Spinoza Grant of the
315 Netherlands Organization for Scientific Research. The graphical abstract was created with
316 BioRender.com.

317 **Declaration of Competing Interests**

318 The authors have declared that no conflict of interest exists.

319 **Author contributions**

320 BB, CY, QdM and JvdV designed the experiments, analyzed data and wrote the manuscript.

321 BB, CY and MdG performed the experiments. AdN, IG, NAFJ, LABJ, MGN and FLvdV were

322 co-investigators on CMO 2020-6344, which provided COVID-19 patient samples. BB, CY, IJ,

323 NR, RD and JvdV were co-investigators on CMO 2020-6359, which provided COVID-19

324 patient samples. MK and PP were co-investigators on CMO 2016-2923, which facilitated

325 COVID-19 ICU patient sampling. MLMH created the graphical abstract and wrote the

326 manuscript. TN and LH helped with analysis of the clinical data. JvdV has full access to all

327 the data in the study and takes responsibility for the integrity of the data. All authors critically

328 reviewed and edited the manuscript. BB and CY share first authorship and AdN and IG are

329 co-second authors, listed in alphabetical order.

330 **References**

- 331 1. Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, O'Meara MJ, et al. A SARS-
332 CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-
333 Repurposing. *bioRxiv*. 2020:2020.03.22.002386.
- 334 2. Wu C, Chen X, Cai Y, Xia Ja, Zhou X, Xu S, et al. Risk Factors Associated With
335 Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019
336 Pneumonia in Wuhan, China. *JAMA Internal Medicine*. 2020.
- 337 3. Lake MA. What we know so far: COVID-19 current clinical knowledge and research.
338 *Clin Med (Lond)*. 2020;20(2):124-7.
- 339 4. Li Z, Wu M, Yao J, Guo J, Liao X, Song S, et al. Caution on Kidney Dysfunctions of
340 COVID-19 Patients. *medRxiv*. 2020:2020.02.08.20021212.
- 341 5. Hirsch JS, Ng JH, Ross DW, Sharma P, Shah HH, Barnett RL, et al. Acute kidney
342 injury in patients hospitalized with COVID-19. *Kidney International*. 2020.
- 343 6. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is
344 associated with in-hospital death of patients with COVID-19. *Kidney International*. 2020.
- 345 7. Schmidt EP, Yang Y, Janssen WJ, Gandjeva A, Perez MJ, Barthel L, et al. The
346 pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during
347 experimental sepsis. *Nat Med*. 2012;18(8):1217-23.
- 348 8. Haeger SM, Yang Y, Schmidt EP. Heparan Sulfate in the Developing, Healthy, and
349 Injured Lung. *Am J Respir Cell Mol Biol*. 2016;55(1):5-11.
- 350 9. Garsen M, Rops AL, Rabelink TJ, Berden JH, van der Vlag J. The role of heparanase
351 and the endothelial glycocalyx in the development of proteinuria. *Nephrol Dial Transplant*.
352 2014;29(1):49-55.
- 353 10. Haraldsson B, Nyström J, Deen WM. Properties of the Glomerular Barrier and
354 Mechanisms of Proteinuria. *Physiological Reviews*. 2008;88(2):451-87.
- 355 11. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al.
356 Endothelial cell infection and endotheliitis in COVID-19. *Lancet*. 2020;395(10234):1417-8.

- 357 12. Sardu C, Gambardella J, Morelli M, Wang X, Marfella R, Santulli G. Is COVID-19 an
358 endothelial disease? Clinical and basic evidence2020.
- 359 13. Salmon AH, Satchell SC. Endothelial glycocalyx dysfunction in disease: albuminuria
360 and increased microvascular permeability. *J Pathol.* 2012;226(4):562-74.
- 361 14. Goldberg R, Meirovitz A, Hirshoren N, Bulvik R, Binder A, Rubinstein AM, et al.
362 Versatile role of heparanase in inflammation. *Matrix Biol.* 2013;32(5):234-40.
- 363 15. Garsen M, Benner M, Dijkman HB, van Kuppevelt TH, Li JP, Rabelink TJ, et al.
364 Heparanase Is Essential for the Development of Acute Experimental Glomerulonephritis. *Am*
365 *J Pathol.* 2016;186(4):805-15.
- 366 16. Gil N, Goldberg R, Neuman T, Garsen M, Zcharia E, Rubinstein AM, et al.
367 Heparanase is essential for the development of diabetic nephropathy in mice. *Diabetes.*
368 2012;61(1):208-16.
- 369 17. Kiyan Y, Tkachuk S, Kurselis K, Shushakova N, Stahl K, Dawodu D, et al.
370 Heparanase-2 protects from LPS-mediated endothelial injury by inhibiting TLR4 signalling.
371 *Sci Rep.* 2019;9(1):13591.
- 372 18. Vlag J, Buijsers B. The Glomerular Endothelium in Diabetic Nephropathy: Role of
373 Heparanase: Pathophysiology and Clinical Aspects. 2019. p. 153-70.
- 374 19. SHI C, WANG C, WANG H, YANG C, CAI F, ZENG F, et al. The potential of low
375 molecular weight heparin to mitigate cytokine storm in severe covid-19 patients: a
376 retrospective clinical study. *medRxiv.* 2020:2020.03.28.20046144.
- 377 20. Zetser A, Levy-Adam F, Kaplan V, Gingis-Velitski S, Bashenko Y, Schubert S, et al.
378 Processing and activation of latent heparanase occurs in lysosomes. *Journal of cell science.*
379 2004;117:2249-58.
- 380 21. Bar-Ner M, Eldor A, Wasserman L, Matzner Y, Cohen IR, Fuks Z, et al. Inhibition of
381 heparanase-mediated degradation of extracellular matrix heparan sulfate by non-
382 anticoagulant heparin species. *Blood.* 1987;70(2):551-7.


- 383 22. Rops AL, van den Hoven MJ, Baselmans MM, Lensen JF, Wijnhoven TJ, van den
384 Heuvel LP, et al. Heparan sulfate domains on cultured activated glomerular endothelial cells
385 mediate leukocyte trafficking. *Kidney Int.* 2008;73(1):52-62.
- 386 23. Cohen-Mazor M, Sela S, Mazor R, Ilan N, Vlodaysky I, Rops AL, et al. Are primed
387 polymorphonuclear leukocytes contributors to the high heparanase levels in hemodialysis
388 patients? *Am J Physiol Heart Circ Physiol.* 2008;294(2):H651-8.
- 389 24. LaRiviere WB, Schmidt EP. The Pulmonary Endothelial Glycocalyx in ARDS: A
390 Critical Role for Heparan Sulfate. *Curr Top Membr.* 2018;82:33-52.
- 391 25. Chowdhury MS, Rathod J, Gernsheimer J. A Rapid Systematic Review of Clinical
392 Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19. *Acad*
393 *Emerg Med.* 2020.
- 394 26. Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, et al. Complement
395 associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19
396 infection: a report of five cases. *Transl Res.* 2020:S1931-5244(20)30070-0.
- 397 27. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and
398 anticoagulation. *Blood.* 2020.
- 399 28. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH interim
400 guidance on recognition and management of coagulopathy in COVID-19. *Journal of*
401 *Thrombosis and Haemostasis.* 2020;18(5):1023-6.
- 402 29. Yee JY, Duffull SB. The effect of body weight on dalteparin pharmacokinetics. A
403 preliminary study. *Eur J Clin Pharmacol.* 2000;56(4):293-7.
- 404 30. Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al.
405 Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label
406 non-randomized clinical trial. *International Journal of Antimicrobial Agents.* 2020:105949.
- 407 31. Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic
408 derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. *Cell*
409 *Discovery.* 2020;6(1):16.

- 410 32. Vidak E, Javoršek U, Vizovišek M, Turk B. Cysteine Cathepsins and their
411 Extracellular Roles: Shaping the Microenvironment. *Cells*. 2019;8(3):264.
- 412 33. Sardu C, Gambardella J, Morelli MB, Wang X, Marfella R, Santulli G. Hypertension,
413 Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A
414 Comprehensive Evaluation of Clinical and Basic Evidence. *J Clin Med*. 2020;9(5).
- 415 34. Sodhi CP, Wohlford-Lenane C, Yamaguchi Y, Prindle T, Fulton WB, Wang S, et al.
416 Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg(9) bradykinin/BKB1R
417 axis and facilitates LPS-induced neutrophil infiltration. *Am J Physiol Lung Cell Mol Physiol*.
418 2018;314(1):L17-I31.
- 419 35. van de Veerdonk F, Netea M, Deuren M, Hoogen F, Mast Q, Bruggemann R, et al.
420 Kinins and Cytokines in COVID-19: A Comprehensive Pathophysiological Approach 2020.
- 421 36. Renne T, Schuh K, Muller-Esterl W. Local bradykinin formation is controlled by
422 glycosaminoglycans. *J Immunol*. 2005;175(5):3377-85.
- 423 37. Guo J, Huang Z, Lin L, Lv J. Coronavirus Disease 2019 (COVID-19) and
424 Cardiovascular Disease: A Viewpoint on the Potential Influence of
425 Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset
426 and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. *Journal of the*
427 *American Heart Association*. 2020;9(7):e016219.
- 428 38. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical
429 indexes from 2019-nCoV infected patients linked to viral loads and lung injury. *Science*
430 *China Life Sciences*. 2020;63(3):364-74.
- 431 39. Kramer A, van den Hoven M, Rops A, Wijnhoven T, van den Heuvel L, Lensen J, et
432 al. Induction of glomerular heparanase expression in rats with adriamycin nephropathy is
433 regulated by reactive oxygen species and the renin-angiotensin system. *J Am Soc Nephrol*.
434 2006;17(9):2513-20.
- 435 40. van den Hoven MJ, Waanders F, Rops AL, Kramer AB, van Goor H, Berden JH, et
436 al. Regulation of glomerular heparanase expression by aldosterone, angiotensin II and
437 reactive oxygen species. *Nephrol Dial Transplant*. 2009;24(9):2637-45.

- 438 41. Lin YJ, Kwok CF, Juan CC, Hsu YP, Shih KC, Chen CC, et al. Angiotensin II
439 enhances endothelin-1-induced vasoconstriction through upregulating endothelin type A
440 receptor. *Biochem Biophys Res Commun.* 2014;451(2):263-9.
- 441 42. Hong HJ, Chan P, Liu JC, Juan SH, Huang MT, Lin JG, et al. Angiotensin II induces
442 endothelin-1 gene expression via extracellular signal-regulated kinase pathway in rat aortic
443 smooth muscle cells. *Cardiovasc Res.* 2004;61(1):159-68.
- 444 43. Garsen M, Lenoir O, Rops ALWMM, Dijkman HB, Willemsen B, van Kuppevelt TH, et
445 al. Endothelin-1 Induces Proteinuria by Heparanase-Mediated Disruption of the Glomerular
446 Glycocalyx. *Journal of the American Society of Nephrology : JASN.* 2016;27(12):3545-51.
- 447 44. Rabelink TJ, van den Berg BM, Garsen M, Wang G, Elkin M, van der Vlag J.
448 Heparanase: roles in cell survival, extracellular matrix remodelling and the development of
449 kidney disease. *Nat Rev Nephrol.* 2017;13(4):201-12.
- 450 45. Blich M, Golan A, Arvatz G, Sebbag A, Shafat I, Sabo E, et al. Macrophage activation
451 by heparanase is mediated by TLR-2 and TLR-4 and associates with plaque progression.
452 *Arterioscler Thromb Vasc Biol.* 2013;33(2):e56-65.
- 453 46. Goodall KJ, Poon IK, Phipps S, Hulett MD. Soluble heparan sulfate fragments
454 generated by heparanase trigger the release of pro-inflammatory cytokines through TLR-4.
455 *PLoS One.* 2014;9(10):e109596.
- 456 47. Gordts Philip LSM, Foley Erin M, Lawrence R, Sinha R, Lameda-Diaz C, Deng L, et
457 al. Reducing Macrophage Proteoglycan Sulfation Increases Atherosclerosis and Obesity
458 through Enhanced Type I Interferon Signaling. *Cell Metabolism.* 2014;20(5):813-26.
- 459 48. Goldberg R, Rubinstein AM, Gil N, Hermano E, Li JP, van der Vlag J, et al. Role of
460 heparanase-driven inflammatory cascade in pathogenesis of diabetic nephropathy.
461 *Diabetes.* 2014;63(12):4302-13.
- 462 49. Goldberg R, Sonnenblick A, Hermano E, Hamburger T, Meirovitz A, Peretz T, et al.
463 Heparanase augments insulin receptor signaling in breast carcinoma. *Oncotarget.*
464 2017;8(12):19403-12.

- 465 50. Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The Cytokine storm in
466 COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system.
467 Cytokine & Growth Factor Reviews. 2020.
- 468 51. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients
469 infected with 2019 novel coronavirus in Wuhan, China. *The Lancet*. 2020;395(10223):497-
470 506.
- 471 52. Boels MGS, Koudijs A, Avramut MC, Sol WMPJ, Wang G, van Oeveren-Rietdijk AM,
472 et al. Systemic Monocyte Chemotactic Protein-1 Inhibition Modifies Renal Macrophages and
473 Restores Glomerular Endothelial Glycocalyx and Barrier Function in Diabetic Nephropathy.
474 *The American Journal of Pathology*. 2017;187(11):2430-40.
- 475 53. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated
476 with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *J*
477 *Thromb Haemost*. 2020;18(5):1094-9.
- 478 54. Negri E, Piloto B, Morinaga L, Jardim C, Lamy S, Ferreira M, et al. Heparin therapy
479 improving hypoxia in COVID-19 patients - a case series. medRxiv. 2020.
- 480 55. Shi C, Wang C, Wang H, Yang C, Cai F, Zeng F, et al. Clinical observations of low
481 molecular weight heparin in relieving inflammation in COVID-19 patients: A retrospective
482 cohort study. medRxiv. 2020.
- 483 56. Thachil J. The versatile heparin in COVID-19. *J Thromb Haemost*. 2020.
- 484 57. Ludwig RJ. Therapeutic use of heparin beyond anticoagulation. *Curr Drug Discov*
485 *Technol*. 2009;6(4):281-9.
- 486 58. Kim S, Jin W, Sood A, Montgomery D, Grant O, Fuster M, et al. Glycosaminoglycan
487 binding motif at S1/S2 proteolytic cleavage site on spike glycoprotein may facilitate novel
488 coronavirus (SARS-CoV-2) host cell entry bioRxiv. 2020.
- 489 59. Wang F, Zhang N, Li B, Liu L, Ding L, Wang Y, et al. Heparin defends against the
490 toxicity of circulating histones in sepsis. *Front Biosci (Landmark Ed)*. 2015;20:1259-70.
491

492 **Figures**



493

494 **Figure 1. COVID-19 patients display increased HPSE activity and elevated levels of**

495 **heparan sulfate in plasma. A.** HPSE activity was increased in plasma of COVID-19

496 patients compared to healthy controls. HPSE activity was measured using an in-house

497 developed ELISA with a specific anti-HS antibody. **B.** HS levels were increased in plasma of

498 COVID-19 patients compared to healthy controls. HS levels were measured by an in-house


499 developed competition ELISA using a specific anti-HS antibody. Data were presented as

500 mean±SEM and tested for normal distribution with D'Agostino & Pearson omnibus normality

501 test and statistical differences were calculated using Mann Whitney test (n=10 healthy; n=48

502 COVID-19, *** p<0.001, **** p <0.0001). HPSE, heparanase; HS, heparan sulfate; Healthy,

503 healthy controls; COVID-19, coronavirus disease-19 patients; AU, arbitrary units.




504


505 **Figure 2. Increased plasma HPSE activity associates with COVID-19 disease severity.**

506 **A.** Plasma HPSE activity was significantly higher in ICU and non-ICU patients compared to
507 healthy controls, and higher in ICU patients compared to non-ICU patients. (n=10 healthy;
508 n=34 non-ICU; n=14 ICU) **B.** HS levels were significantly increased in plasma of ICU and
509 non-ICU patients compared to healthy controls (n=10 healthy; n=34 non-ICU; n=14 ICU) **C.**
510 HPSE activity was significantly higher in plasma of patients with mechanical ventilation
511 compared to patients without mechanical ventilation. (n=33 not ventilated; n=15 mechanical
512 ventilation) **D.** HPSE activity was significantly higher in plasma of patients with elevated LDH
513 (>280 U/l) values compared to patients with normal LDH levels. (n=15 normal LDH; n=26
514 elevated LDH). **E.** HPSE activity was significantly higher in plasma of patients with elevated
515 creatinine (>110 $\mu\text{mol/l}$ for men and >90 $\mu\text{mol/l}$ for women) values compared to patients with
516 normal creatinine values. (n=30 normal creatinine; n=11 elevated creatinine; patients with

517 history of renal disease were excluded from this analysis). HPSE activity was measured
518 using an in-house developed ELISA with a specific anti-HS antibody. Data were presented
519 as mean±SEM and tested for normal distribution with D'Agostino & Pearson omnibus
520 normality test and statistical differences were calculated using Kruskal Wallis test followed
521 by Dunn's multiple comparison test, unpaired one-tailed Student's t-test or unpaired one-
522 tailed Mann Whitney test (* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001). HPSE,
523 heparanase; HS, heparan sulfate; LDH, lactate dehydrogenase; Healthy, healthy controls;
524 non-ICU: COVID-19 patients in normal hospital ward; ICU, COVID-19 patients in ICU; AU,
525 arbitrary units.
526



527
528 **Figure 3. LMWH reduces plasma HPSE activity in moderately diseased COVID-19**
529 **patients. A.** LMWH reduces HPSE activity in plasma of non-ICU patients with COVID-19,
530 which was measured using in house developed HPSE activity assay. (n=17 for both groups,
531 p<0.05). Data were presented as mean±SEM and tested for normal distribution with
532 D'Agostino & Pearson omnibus normality test and statistical difference was calculated using
533 unpaired one-tailed Mann Whitney test. **B.** LMWH inhibits recombinant HPSE activity *in vitro*
534 in a dose dependent manner. HPSE activity was measured using an in-house developed
535 ELISA with a specific anti-HS antibody. (n=3)



536

537 **Supplementary Figure 1. HPSE activity was similar in the plasma of chloroquine**

538 **treated COVID-19 patients. A.** Plasma from non-ICU patients with or without CQ treatment

539 had similar HPSE activity levels. (n=21 CQ-; n=12 CQ+). Data was tested for normal

540 distribution with D'Agostino & Pearson omnibus normality test and statistical difference was

541 calculated using unpaired one-tailed Mann Whitney test. **B.** Plasma from ICU patients with or

542 without CQ treatment had similar HPSE activity levels. (n=8 CQ-; n=6 CQ+).

543 **Table**

544 **Table 1. Demographics and baseline characteristic of COVID-19 patients***

Characteristics	All patients n=48	ICU n=14	Non-ICU		Total n=34	p ₁	p ₂
			LMWH- n=17	LMWH+ n=17			
Sex, male, n (%)	37 (77)	11 (78.5)	13 (76.5)	13 (76.5)	26 (76.5)	1.0000	1.0000
Age, median (IQR), yr	67.5 (57.3-74.75)	62.5 (53.0-69.5)	69 (62.5-76.5)	69 (53.5-77.0)	69 (58.8-77.0)	0.6792	0.2428
Hospital stay, median (IQR), days	9 (5-16)	26 (16-...)&	5 (5-8)	9 (6-12)	7 (5-9)	0.0443	0.0001
Day of sampling (IQR)	2 (1-3)	3 (1-6)	1 (1-2)	2 (2-4)	2 (1-3)	0.0089	0.1378
Coexisting disorder, n (%)							
Heart disease	8 (16.7)	3 (21.4)	3 (17.6)	2 (11.8)	5 (14.7)	1.0000	0.6757
Lung disease	16 (33.3)	4 (28.6)	2 (11.8)	10 (58.8)	12 (35.3)	0.0104	0.7460
Diabetes	6 (12.5)	2 (14.3)	3 (17.6)	1 (5.9)	4 (11.8)	0.6012	1.0000
Hypertension	18 (37.5)	8 (72.7)	5 (29.4)	5 (29.4)	10 (29.4)	1.0000	0.1032
Malignancy	9 (18.8)	1 (7.1)	4 (23.5)	4 (23.5)	8 (23.5)	1.0000	0.2501
Immunocompromised	7 (14.6)	0 (0)	2 (11.8)	5 (29.4)	7 (20.6)	0.3983	0.0898
Renal disease	4 (8.3)	2 (14.3)	0 (0)	2 (11.8)	2 (5.9)	0.4848	0.5659
COVID-19 treatment, n (%)							
(hydroxy)chloroquine	19 (39.6)	6 (42.9)	4 (42.9)	9 (52.9)	13 (38.2)	0.1571	1.0000
Remdesivir	1 (2.1)	1 (7.1)	0 (0.0)	0 (0.0)	0 (0.0)	NA	0.1153
CT severity score*, median (IQR)	NA	NA	9.0 (7.3-13.0) ⁺	13.0 (9.3-16.5) ⁺	11.5 (8.0-15.0) ⁺⁺	0.0743	NA
Laboratory, median (IQR)							
WBC, x10 ⁹ /l*	6.8 (5.2-9.1) ⁺	6.7 (5.9-7.9)	6.0 (4.0-8.9) ⁺	7.4 (4.8-9.8)	6.8 (4.5-9.8) ⁺	0.5077	0.9722
Platelets, x10 ⁹ /l*	213 (158-279) ⁺	220 (176-281)	164 (137-219) ⁺	250 (189-330)	201 (149-286) ⁺	0.0306	0.9706
C-reactive protein, mg/l*	93 (55-170) ⁺⁺	171 (120-258) ⁺	81 (54-122) ⁺	78 (41-136) ⁺⁺	79 (49-122)	0.6786	0.0007
Ferritin, µg/l	973 (567-1658)	1363 (872-1917)	788 (259-1018)	950 (571-1854)	871 (472-1369)	0.2214	0.1149
D-dimer, ng/ml*	1090 (315-2075) ⁺⁺⁺⁺⁺	1870 (313-5275) ⁺	369 (199-883) ⁺	1335 (1130-2775) ⁺⁺⁺⁺	940 (311-1510) ⁺⁺⁺⁺⁺	0.0008	0.1199
Lactate dehydrogenase, U/l*	309 (258-407) ⁺	306 (273-399)	302 (238-440) ⁺	317 (259-362)	314 (257-414) ⁺	0.8430	0.9907
Creatinine, µmol/l*#	92.0 (71.0-115.5) ⁺⁺⁺⁺	101.0 (73.0-145.5) ⁺⁺	94.0 (78.0-115.8)	85.0 (62.3-97.8) ⁺⁺	89.5 (70.0-110.8) ⁺⁺	0.2500	0.2814

545 * Data are presented as median (IQR) or percentage (%). P values comparing LMWH- with
546 LMWH+ patients (p_1) or ICU patients with non-ICU patients (p_2) are calculated with Fisher's
547 exact test, unpaired two-tailed Student's t test or unpaired two-tailed Mann Whitney test.
548 ICU, intensive care unit; COVID-19, coronavirus disease-2019; IQR, interquartile range;
549 LMWH-, patients without prophylactic LMWH; LMWH+, patients with prophylactic LMWH.
550 Measurements with missing values are indicated with * and the number of + signs indicates
551 the number of missing patients per characteristic and group. & 75% quartile is unknown due
552 to prolonged hospitalization of some patients. # 4 patients with history of renal disease were
553 excluded.